Evidence map›Paper›PMID 42238569›Full record

ArticleFrontiers in immunology2026

Fucosyltransferase 4-derived peptide bioconjugates on carbon nanotubes enhance antitumor immunity in an ovarian cancer mouse model.

J J Guzmán-Mendoza, B Sánchez-Ramírez, A Velarde-Calderón, A M González-González, C García-Campuzano, A Jiménez-Bernal, L U López-Bailón, P Talamás-Rohana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J J Guzmán-MendozaDepartamento de Infectómica y Patogénesis Molecular. Centro de Investigación y de Estudios Avanzados, Ciudad de México, Mexico.
B Sánchez-RamírezFacultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Chihuahua, Mexico.
A Velarde-CalderónDepartamento de Infectómica y Patogénesis Molecular. Centro de Investigación y de Estudios Avanzados, Ciudad de México, Mexico.
A M González-GonzálezLaboratorio de Investigación en Nano y Biomateriales Dentales, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
C García-CampuzanoDepartamento de Infectómica y Patogénesis Molecular. Centro de Investigación y de Estudios Avanzados, Ciudad de México, Mexico.
A Jiménez-BernalDepartamento de Infectómica y Patogénesis Molecular. Centro de Investigación y de Estudios Avanzados, Ciudad de México, Mexico.
L U López-BailónDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, United States.
P Talamás-RohanaDepartamento de Infectómica y Patogénesis Molecular. Centro de Investigación y de Estudios Avanzados, Ciudad de México, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is characterized by a profoundly immunosuppressive tumor microenvironment, which has limited the clinical success of immunotherapy approaches. Antigen-based nanovaccines represent a promising strategy to enhance antitumor immunity by improving antigen delivery and immune activation. In this study, we evaluated carbon nanotubes (CNTs) bioconjugated with a peptide derived from tumor-associated antigen fucosyltransferase 4 (FUT4) as an immunomodulating platform in an immunocompetent ovarian cancer mouse model. FUT4 expression was confirmed in the ID8-Defb29/Vegf-a (ID8DVLuc) ovarian cancer model using flow cytometry and confocal microscopy. C57BL/6 mice were immunized with free peptide combined with a conventional adjuvant (PEP37 Adj), FUT4 peptide-conjugated CNTs (

Indexed as

Cancer VaccinesFucosyltransferasesNanotubes, CarbonOvarian NeoplasmsPeptidesAnimalsCell Line, TumorDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLNanovaccinesProtein Subunit VaccinesCancer VaccinesFucosyltransferasesFut4 protein, mouseNanotubes, CarbonNanovaccinesPeptidesProtein Subunit Vaccinesantigen-based nanovaccinecarbon nanotubesCD8 T cell immunitynanotechnology-based immunotherapyovarian cancertumor-associated antigen

Identifiers

PMID42238569
PMCPMC13226612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.